Paper Details

  1. Home
  2. Paper Details

Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.

Author: ApplebeeAngela, BethouxFrancois, BlightAndrew R, CarrazanaEnrique J, GoldmanMyla D, GoodmanAndrew D, KlinglerMichael, MayadevAngeli S

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A subgroup analysis of 153 patients with multiple sclerosis (MS) from a randomized, placebo-controlled, double-blind study found that dalfampridine extended-release (ER) 10 mg BID, but not 5 mg BID, was associated with statistically significant and clinically meaningful improvements in walking speed and distance walked compared to placebo. The study suggests that dalfampridine ER 10 mg BID is effective for improving walking in people with MS.
Paper Details　
Original Abstract of the Article :
PURPOSE: Dalfampridine extended-release (ER) tablets 10 mg BID have been approved for use in improving walking in people with multiple sclerosis (MS). This subgroup analysis evaluated the effects of dalfampridine ER 5 and 10 mg BID on distance walked, as assessed using the 6-minute walk (6MW) test. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clinthera.2015.10.014

データ提供：米国国立医学図書館（NLM）

Dalfampridine: A Potential Treatment for Multiple Sclerosis

[Multiple sclerosis (MS)] is a chronic neurological disease that affects the [central nervous system]. This study investigates the effectiveness of [dalfampridine extended-release (ER) tablets] in improving [walking ability] in [patients with MS]. The authors used [a post hoc analysis of data from a randomized controlled trial] to examine the [effects of dalfampridine ER] on [walking distance and speed] in [patients with MS]. The study reveals that [dalfampridine ER 10 mg BID was significantly more effective than placebo in improving walking distance and speed, meeting a minimal clinically important difference (MCID)]. This finding suggests that [dalfampridine ER] may be a valuable treatment option for [improving walking ability in patients with MS].

Dalfampridine: A Step Forward for Patients with MS

The study found that [dalfampridine ER 10 mg BID] can significantly improve [walking ability] in [patients with MS]. It’s like a camel finding a path through a treacherous desert landscape – [dalfampridine ER] can provide a [boost and support] for those struggling with [the challenges of MS].

Hope for Improved Mobility

This study provides encouraging evidence for the [potential of dalfampridine ER in managing MS]. The findings suggest that [dalfampridine ER] may offer a new approach to [improving mobility] in [patients with MS]. It’s a reminder that [research is constantly advancing], and [new therapies are being developed] all the time.

Dr.Camel's Conclusion

This study highlights the effectiveness of [dalfampridine ER] in [improving walking ability] in [patients with MS]. It’s a reminder that [science is constantly evolving], and [new discoveries are being made] all the time. The findings suggest that [dalfampridine ER] may offer a new weapon in the fight against [the limitations of MS].

Date :
  1. Date Completed 2016-08-05
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

26565077

DOI: Digital Object Identifier

10.1016/j.clinthera.2015.10.014

Related Literature

Article Analysis
・Effects of dalfampridine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.